March 7-9, 2022
Digital Event

Uncovering the Clinical Research Propelling ILD Drug Development Forwards in 2022 & Beyond

8:30 am Registration & Networking

8:55 am Chair’s Opening Remarks

9:00 am Strategically Leveraging ILD Clinical Trials to Further Our Understanding of The Progressive Pulmonary Fibrosis Phenotype & Identify Novel Outcomes in Clinical Trials

• Craig Conoscenti Medical Expert ILD Respiratory Clinical Development & Medical Affairs, Boehringer Ingelheim

9:30 am Looking Beyond IPF: Utilizing Lessons Learned from IPF Clinical Trials to Inform & Optimize Your ILD Trial Design & Execution

• Eric White Senior Clinical Program Lead, Boehringer Ingelheim

10:00 am Uncovering Trial Design Considerations in Sarcoid

• Majd Mouded Executive Director for BioMedical Research, Novartis

10:30 am Speed Networking

11:00 am Morning Break & Networking

Uncovering Emerging ILD Therapeutic Approaches

11:30 am Developing Therapies for Rare Lung Diseases: ILD 101

• Rohit Batta Chief Scientific Officer, Vicore Pharma

12:00 pm Lunch Break & Networking

1:00 pm Single vs Multiple Benefit Drugs for ILD

• Matt Bradley Founder, Chairman, President, & Chief Technical Officer, SAJE Pharma

1:30 pm Update on Inhaled Drug Delivery: The Application of Anticalins in the Treatment of Lung Fibrosis

• Vanessa Neins Senior Scientist - Biology Lead Respiratory, Pieris Pharmaceuticals

Analyzing & Scrutinizing ILD Mechanisms

2:00 pm Evolution of Multicellular Hubs in the Tumor Microenvironment & their Relevance for ILD Drug Development

• Shannon Turley Vice President of Cancer Immunology Discovery, Genentech

2:30 pm The Role of Macrophage Metabolic Reprogramming During Pulmonary Fibrosis

• Adam Byrne Professor, Imperial College London

3:00 pm Afternoon Break & Networking

Strategizing New Target Identification for Novel Therapies 101

4:00 pm Selective Inhibition of ROCK2: Promising Approach to Target Fibrosis

• Nicolas Guisot Research Fellow & Project Leader, Redx Pharma

4:30 pm Revealing What Steps You Must Take to Successfully Identify & Validate Novel ILD Therapeutic Targets which Target Lung Epithelial injury

• Glenn Rosen Chief Scientific Officer, Optikira & Biomotiv

5:00 pm Chair’s Closing Remarks

5:05 pm End of Conference Day Two